TriSalus Life Sciences, Inc.TLSI
What TriSalus Life Sciences, Inc. does.
Unless the context indicates otherwise, references in this Annual Report to the “Company,” “TriSalus,” “we,” “us,” “our” and similar terms refer to TriSalus Life Sciences, Inc. (f/k/a MedTech Acquisition Corp.), a Delaware corporation and its consolidated subsidiaries.
We are a growing, oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 ("TRL9") agonist, for a range of different therapeutic and technology applications. Our ultimate goal is to transform the treatment paradigm for patients battling solid tumors. We have developed an innovative technology designed to overcome two of the most significant challenges that prevent optimal delivery and performance of therapeutics in these difficult-to-treat diseases: (i) high intratumoral pressure caused by tumor growth and collapsed vasculature restricting the delivery of oncology therapeutics and (ii) off target delivery. Nelitolimod, specifically, combined with our technology aims to address the immunosuppressive properties of tumor immune cells in liver, pancreas and other solid tumors. By systematically addressing these barriers, we aim to improve response to therapies and to enable improved patient outcomes.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $12.4M | $18.5M | $29.4M | $45.2M |
| Net income | — | $4.8M | -$47.2M | -$59.4M | -$30.0M | -$39.2M |
| Free cash flow | — | — | -$33.0M | -$51.2M | -$41.2M | -$18.9M |
More on TLSI.
- TriSalus Life Sciences, Inc. summary
- TriSalus Life Sciences, Inc. financial statements
- TriSalus Life Sciences, Inc. key metrics
- TriSalus Life Sciences, Inc. health scores and style box
- TriSalus Life Sciences, Inc. earnings
- TriSalus Life Sciences, Inc. dividends
- TriSalus Life Sciences, Inc. valuation
- TriSalus Life Sciences, Inc. ownership and insiders
- TriSalus Life Sciences, Inc. peers
Figures from TriSalus Life Sciences, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.